A Discussion on the Coronavirus (SARS-COV-2)

Mar 16, 2020 | Blog | 0 comments

Daniel Gigante

Brett Averso, CTO, and I linked up to discuss the coronavirus (SARS-CoV-2). Brett covered what exactly the coronavirus is, the threat it currently presents (attention given to relative threat with respect to the original SARS virus [SARS-CoV] and MERS [MERS-CoV]), how we can best protect ourselves and our loved ones against infection, and what EVQLV is doing to address the outbreak. Watch our entire discussion below.

The discussion regarding the incubation period is supported by research performed by a Johns Hopkins lead study published in the Annals of Internal Medicine. Our discussion regarding the Case-Fatality Rate (CFR) was provided by the Chinese CDC and published by Jama Network on February 24th. We’ve constructed relevant pie charts based upon their data below.

n = 44672. Data above independent of demographics

For additional tips on how to keep you and your loved ones safe, view the CDC guidelines.

For more information on EVQLV’s work on combatting coronavirus, view Immunoprecise’s press release.

As Brett suggested, we recommend investigating the latest research without the news hype on the coronavirus with Google Scholar. Two examples below.

1. Sars-CoV-2

2. COVID-19


Submit a Comment

Your email address will not be published. Required fields are marked *

NY Bio-Computation Startup EVQLV Closes Financing Round

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...

Fully Automated Rabbit Humanization Project Initiated w/ U Buffalo

NEW YORK, December 16, 2020 -- EVQLV is eagerly anticipating the results from the second phase of their University at Buffalo rabbit-humanization collaboration. Starting with rabbit monoclonal antibodies, EVQLV is attempting to validate its fully-automated...

EVQLV Accepted to Prestigious Techstars Boston Accelerator

NEW YORK, November 18, 2020 -- EVQLV, a New York company that uses AI to accelerate the development of antibodies, will be one of 10 startups in the new class of the Techstars Boston program. This year’s program will be 100% virtual and, for the first time, will...

Pin It on Pinterest